PRME Valuation

Prime Medicine Inc

Add to Watchlist

Advanced Chart

4.180

-0.22(-5.000%)1D

PRME Relative Valuation

PRME's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRME is overvalued; if below, it's undervalued.

Historical Valuation

Prime Medicine Inc (PRME) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.40 is considered Undervalued compared with the five-year average of -4.95. The fair price of Prime Medicine Inc (PRME) is between 13.53 to 26.87 according to relative valuation methord. Compared to the current price of 4.30 USD , Prime Medicine Inc is Undervalued By 68.21%.

Relative Value

Fair Zone

13.53-26.87

Current Price：4.30

68.21%

Undervalued

-4.69

Trailing

Forward

-4.99

EV/EBITDA

Prime Medicine Inc. (PRME) has a current EV/EBITDA of -4.99. The 5-year average EV/EBITDA is -4.03. The thresholds are as follows: Strongly Undervalued below -10.82, Undervalued between -10.82 and -7.43, Fairly Valued between -0.64 and -7.43, Overvalued between -0.64 and 2.76, and Strongly Overvalued above 2.76. The current Forward EV/EBITDA of -4.99 falls within the Historic Trend Line -Fairly Valued range.

-6.17

EV/EBIT

Prime Medicine Inc. (PRME) has a current EV/EBIT of -6.17. The 5-year average EV/EBIT is -4.13. The thresholds are as follows: Strongly Undervalued below -10.90, Undervalued between -10.90 and -7.51, Fairly Valued between -0.75 and -7.51, Overvalued between -0.75 and 2.64, and Strongly Overvalued above 2.64. The current Forward EV/EBIT of -6.17 falls within the Historic Trend Line -Fairly Valued range.

4.40

Prime Medicine Inc. (PRME) has a current PS of 4.40. The 5-year average PS is 141.94. The thresholds are as follows: Strongly Undervalued below -285.80, Undervalued between -285.80 and -71.93, Fairly Valued between 355.81 and -71.93, Overvalued between 355.81 and 569.68, and Strongly Overvalued above 569.68. The current Forward PS of 4.40 falls within the Historic Trend Line -Fairly Valued range.

-6.37

P/OCF

Prime Medicine Inc. (PRME) has a current P/OCF of -6.37. The 5-year average P/OCF is -5.68. The thresholds are as follows: Strongly Undervalued below -12.89, Undervalued between -12.89 and -9.29, Fairly Valued between -2.07 and -9.29, Overvalued between -2.07 and 1.53, and Strongly Overvalued above 1.53. The current Forward P/OCF of -6.37 falls within the Historic Trend Line -Fairly Valued range.

-5.90

P/FCF

Prime Medicine Inc. (PRME) has a current P/FCF of -5.90. The 5-year average P/FCF is -4.83. The thresholds are as follows: Strongly Undervalued below -10.56, Undervalued between -10.56 and -7.69, Fairly Valued between -1.96 and -7.69, Overvalued between -1.96 and 0.90, and Strongly Overvalued above 0.90. The current Forward P/FCF of -5.90 falls within the Historic Trend Line -Fairly Valued range.

Prime Medicine Inc (PRME) has a current Price-to-Book (P/B) ratio of 9.47. Compared to its 3-year average P/B ratio of 3.91 , the current P/B ratio is approximately 142.52% higher. Relative to its 5-year average P/B ratio of 3.81, the current P/B ratio is about 148.32% higher. Prime Medicine Inc (PRME) has a Forward Free Cash Flow (FCF) yield of approximately -0.16%. Compared to its 3-year average FCF yield of -27.80%, the current FCF yield is approximately -99.41% lower. Relative to its 5-year average FCF yield of -27.49% , the current FCF yield is about -99.40% lower.

9.47

P/B

Median3y

3.91

Median5y

3.81

-0.16

FCF Yield

Median3y

-27.80

Median5y

-27.49

Competitors Valuation Multiple

The average P/S ratio for PRME's competitors is 19.80, providing a benchmark for relative valuation. Prime Medicine Inc Corp (PRME) exhibits a P/S ratio of 4.40, which is -77.77% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Palvella Therapeutics Inc

Performance Decomposition

Market capitalization of PRME increased by 33.74% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 0.00 to 1.12M.

The secondary factor is the Margin Expansion, contributed -72.42%to the performance.

Overall, the performance of PRME in the past 1 year is driven by Revenue Growth. Which is more sustainable.

NaN%

0.00 → 1.12M

Revenue Growth

-72.42%

-17.10K → -4.72K

Margin Expansion

NaN%

0.00 → -2.80

P/E Change

33.74%